Despite Celgene Corp.'s low expectations regarding Revlimid's ability as a monotherapy in the difficult indication of metastatic malignant melanoma patients who already had failed two lines of therapy, the firm's stock dipped on stopping a Phase III trial in that indication. (BioWorld Today) Read More